Actively Recruiting
Walking Sensation Study
Led by University of Florida · Updated on 2026-02-09
30
Participants Needed
1
Research Sites
81 weeks
Total Duration
On this page
Sponsors
U
University of Florida
Lead Sponsor
T
The Claude D. Pepper Older Americans Independence Centers
Collaborating Sponsor
AI-Summary
What this Trial Is About
The primary objective of this new line of research is to test whether augmenting sensory information from the legs, using Walkasins sensory neuroprosthesis, can enhance performance of a complex walking task in older adults with foot sensory impairment. The overarching hypothesis is that Walkasins will enhance the automaticity and reduce cognitive demand of walking in older adults with foot sensory impairments, as measured by reduced prefrontal activity, decreased dual-task costs, and lower gait variability.
CONDITIONS
Official Title
Walking Sensation Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 65 to 95 years old
- No significant medical conditions, health issues, or medications that could interfere with walking or assessments
- No severe high blood pressure (systolic less than 180 mmHg and/or diastolic less than 100 mmHg at rest)
- No severe vision impairment (visual acuity 20/70 or better as measured by Snellen eye chart)
- Preferred walking speed slower than 1.0 meter per second over 10 meters
- No cognitive impairment (Montreal Cognitive Assessment score 26 or higher out of 30)
- Foot sensory impairment defined as inability to feel the 10 g monofilament at one or more of 10 tested sites on either foot
You will not qualify if you...
- Diagnosed neurological disorders or injuries of the central nervous system (e.g., Alzheimer's, Parkinson's, stroke)
- Severe arthritis such as awaiting joint replacement
- Current cardiovascular, lung, or kidney disease; untreated diabetes; terminal illness
- Heart attack or major heart surgery in the past year
- Cancer treatment in the past year except for nonmelanoma skin cancers or cancers with excellent prognosis
- Diagnosis of schizophrenia, other psychotic disorders, or bipolar disorder
- Taking medications that affect the central nervous system (e.g., benzodiazepines, anti-cholinergic, GABAergic medications)
- Severe vision impairment (visual acuity worse than 20/70)
- Uncontrolled hypertension at rest (systolic over 180 mmHg and/or diastolic over 100 mmHg)
- Bone fracture or joint replacement in the past six months
- Current enrollment in another clinical trial
- Planning to move away during the study period
- Non-English speaking
- Clinical judgment of the investigative team
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Clinical and Translational Research Building
Gainesville, Florida, United States, 32610
Actively Recruiting
Research Team
S
Shravani Chobhe
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here